Navigation Links
PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
Date:8/25/2008

onomic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, Perceptive Informatics is a trademark of Perceptive Informatics, Inc., and ClinPhone is a registered trademark of ClinPhone Limited. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

Contacts:

Jennifer Baird, Senior Director of Public Relations Rebecca Passo

PAREXEL International SHIFT Communications

Tel: +781-434-4409 Tel : +617-681-1817

Jennifer.Baird@PAREXEL.com rpasso@shiftcomm.com


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Md. , Dec. 17, 2014  United Therapeutics ... senior executive promotions as well as changes to ... Senior Executive Promotions United Therapeutics announced ... President and Co-Chief Executive Officer and David Zaccardelli ... Officer.  In connection with these promotions, Dr. Rothblatt,s title ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 METTLER ... inline PVM tool, ParticleView V19 with PVM ... situ probe-based particle vision and measurement tool continuously ... process conditions. ParticleView V19 then automatically prepares a ... tracking particle size and concentration changes. This compelling ...
(Date:12/15/2014)... 2014 Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology,  today celebrated continued ... its exVive3D TM Human Liver Tissue.  The ... commercial release on November 18, has been recognized ... awards for innovation. Most recently, on ...
Breaking Biology Technology:United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 2Organovo Celebrates a Positive 2014 Reception of its exVive3DTM Human Liver Tissue Product 3
... 2007 versus $5.2 Million ... for Q3 of 2006, -- Gross profit increases 102% to $2.6 Million for ... Million ... Debt to Equity, BEIJING, Nov. 23 /Xinhua-PRNewswire/ -- China Biopharmaceuticals,Holdings, Inc. (OTC Bulletin Board: ...
... Bristol-,Myers Squibb Company (NYSE: BMY ) ... terminating their license agreement for the development of,vinflunine, ... of,advanced or metastatic bladder cancer and other tumor ... licensed to Bristol-Myers Squibb,in 2004 for specific territories. ...
... November 22 ,Essilor yesterday cancelled 700,000 shares as ... dilutive impact of stock option and performance,share plans., ... of Directors authorized the,granting of 930,740 stock options ... potentially lead to the issuance of up to,1,507,004 ...
Cached Biology Technology:China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 2China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 3China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 4China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 5China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 6China Biopharmaceuticals Holdings Announces Third Quarter 2007 Financial Results 7
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... of stem cells such as regenerating damaged tissues or ... the past decade. While these types of applications are exciting, ... most immediate impact of stem cells on human health will ... new drugs. , The ability to generate stem cells by ...
... preservative, may slow or stop squamous cell head and neck ... What makes this particularly good news is that the Food ... as safe for human consumption decades ago, says Yvonne Kapila, ... Michigan School of Dentistry. This means that ...
... release is available in German . ... is a promising anode material for photoelectro-chemical cells (PEC) because ... to the solar spectrum. Although it has the potential of ... lower than that of other metal oxides. This is due ...
Cached Biology News:The role of stem cells in developing new drugs 2Common food preservative may slow, even stop tumor growth 2The hunt for electron holes 2The hunt for electron holes 3
... Rabbit monoclonal [EP282Y] to Asparagine ... all tested applications). ... corresponding to residues in the ... Entrez GeneID: ...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 25 tests...
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Anti-Cohesin (Scc1/Rad21) Monoclonal Antibody Research Focus: signal transduction Storage: -20C Shipping Temperature: +4C...
Biology Products: